In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”
Our supporting partners do not constitute an endorsement of the content on this page.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, ...
Expert insights on new and emerging approaches to optimize the management of steroid-refractory cGvHD.
Three experts discuss data presented at ASH 2024 on BCMA-targeting agents in multiple myeloma.
Bruton tyrosine kinase (BTK) plays a functional and integral role in B-cell receptor (BCR) signalling and is expressed in normal and malignant B cells. Given BTK’s central role in the survival and proliferation of malignant B cells, BTK inhibitors ...
Prof. Pierre Fenaux, Head of the Department of  Hematology and Immunology at Assistance Publique-Hôpitaux de Paris Nord (Hôpitaux Saint-Louis, R Debré, Avicenne) is a leading expert in haematology with extensive experience in the treatment and management of myelodysplastic syndromes (MDS). In this interview, he discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.
Watch this touchCONGRESS activity exploring advances in treatments for patients with CML, based on data from 2024 congresses, including EHA and ESH-iCMLf.
Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.
In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
At this year’s European Society for Blood and Marrow Transplantation (EBMT) meeting in Glasgow, Scotland, graft-versus-host disease (GVHD) emerged as a central topic of discussion. The conference featured a wealth of innovative research, with numerous abstracts presenting advances in the management of chronic and refractory GVHD, offering new hope for patients facing this challenging complication. Here we explore some of the most exciting abstracts presented.
Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms. In this episode, we speak with Prof. John Mascarenhas, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.
Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.